US FDA greenlights Regeneron's blood cancer drug
Regeneron's new drug, Lynozyfic, just got the green light from the FDA to treat advanced multiple myeloma—a tough type of blood cancer—for people who've already tried at least four other treatments.
In trials, 70% of patients saw their cancer shrink or disappear, which is a big step forward for folks running out of options.
Lynozyfic helps the immune system find and attack cancer cells
Lynozyfic is a bispecific antibody that helps the immune system find and attack cancer cells. Nearly half of trial participants even reached complete remission.
Regeneron's shares ticked up after the news, and they're rolling out the drug soon—though it comes with a hefty price tag ($470 for 5mg; $18,800 for 200mg).
With over 36,000 new US cases expected next year, this could be a game-changer for those needing more treatment options.